首頁 > 市場調查報告書 > 製藥

生物製劑

蛋白質療法市場規模、佔有率和成長分析（按類型、應用、最終用戶、功能和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1902990

蛋白質療法市場規模、佔有率和成長分析（按類型、應用、最終用戶、功能和地區分類）—產業預測（2026-2033 年）

Protein Therapeutics Market Size, Share, and Growth Analysis, By Type (Monoclonal Antibodies, Insulin), By Application (Metabolic Disorders, Cancer), By End User, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球蛋白質療法市場規模將達到 3,722 億美元，從 2025 年的 3,983.6 億美元成長到 2033 年的 6,860 億美元，在預測期（2026-2033 年）內複合年成長率為 7.03%。

對多種疾病有效治療方法的日益成長的需求正顯著推動蛋白質療法市場的發展。隨著糖尿病、自體免疫疾病和癌症等慢性疾病日益普遍（主要受人口老化影響），對蛋白質治療方法的需求也隨之增加。與傳統的小分子藥物不同，生物製藥因其療效較佳、副作用較少、特異性較高而備受青睞。單株抗體在蛋白質工程和生物技術進步的推動下，引領著蛋白質療法領域的發展。這種創新環境正促進下一代生物製劑的研發，包括融合蛋白和雙特異性抗體。慈善機構和政府的獎勵推動了罕見疾病研究的進展，而隨著原研究生物製劑專利的到期，生物相似藥的推出進一步推動了市場的發展，改善了不同患者群體獲得治療的機會。

蛋白質療法市場促進因素

全球蛋白質療法市場的主要促進因素之一是癌症、糖尿病和自體免疫疾病等慢性疾病的日益普遍。隨著這些疾病負擔的加重，人們對創新有效的治療方案（包括蛋白質治療方法）的需求也日益成長。這些療法具有標靶作用機制，與傳統療法相比，能夠帶來更好的患者療效和更少的副作用。此外，生物技術和基因組學的進步正在推動新型蛋白質療法的研發，進一步促進市場成長，並吸引製藥公司和研究機構的大量投資。

蛋白質療法市場面臨的限制

全球蛋白質療法市場的主要限制因素之一是蛋白質藥物研發和生產過程的高成本。蛋白質工程的複雜性，加上嚴格的監管核准要求，會導致漫長而昂貴的研發階段。此外，生物製藥的生產通常需要專門的設施和設備，進一步推高了成本。這些經濟壁壘會限制中小型生物技術公司的進入，扼殺創新，最終影響市場供應和患者獲得新型治療方案的機會。因此，高成本可能會阻礙整個市場的成長和蛋白質療法的廣泛應用。

蛋白質療法市場趨勢

蛋白質療法市場正經歷著顯著的個人化趨勢，這主要源於對根據個體基因和分子特徵量身定做的治療方案日益成長的需求。這種轉變不僅提高了治療效果，還最大限度地減少了副作用，使治療方案對醫療服務提供者和患者都更具吸引力。隨著癌症和自體免疫疾病等疾病的日益普遍，標靶生物製藥和先進蛋白質療法的應用正在加速。這一發展趨勢反映了醫療保健領域向精準醫療邁進的更廣泛趨勢，並刺激了對先進治療方法研發的創新和投資，這些療法有望改善患者預後並提高整個醫療保健系統的效率。

Johnson & Johnson（United States）
Roche（Switzerland）
Merck & Co.（United States）
Pfizer（United States）
AbbVie（United States）
Sanofi（France）
AstraZeneca（United Kingdom）
Novartis（Switzerland）
Bristol-Myers Squibb（United States）
Abbott Laboratories（United States）
GlaxoSmithKline（United Kingdom）
Novo Nordisk（Denmark）
Eli Lilly and Company（United States）
Amgen（United States）
Gilead Sciences（United States）
Biogen（United States）
Bayer（Germany）
Takeda Pharmaceutical Company（Japan）
CSL Behring（Australia）
Teva Pharmaceutical Industries（Israel）

結論與建議

簡介目錄

Product Code: SQMIG35H2238

Protein Therapeutics Market size was valued at USD 372.2 Billion in 2024 and is poised to grow from USD 398.36 Billion in 2025 to USD 686 Billion by 2033, growing at a CAGR of 7.03% during the forecast period (2026-2033).

The rising demand for effective treatments addressing multiple ailments has significantly boosted the protein therapeutics market. As chronic diseases such as diabetes, autoimmune disorders, and cancer become more prevalent, driven largely by an aging population, the need for protein-based therapies intensifies. Unlike traditional small-molecule drugs, biologics offer superior efficacy, reduced side effects, and increased specificity, resulting in their growing popularity. Monoclonal antibodies lead the protein therapy segment, supported by advances in protein engineering and biotechnology. This innovative landscape fosters the development of next-generation biologics, including fusion proteins and bispecific antibodies. Charitable initiatives and government incentives are advancing research on rare diseases, while the introduction of biosimilars further evolves the market as patents for original biologics expire, enhancing treatment accessibility for diverse patient populations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

One key market driver for the global protein therapeutics market is the increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders. As the burden of these conditions rises, there is a growing demand for innovative and effective treatment options, including protein-based therapies. These therapeutics offer targeted mechanisms of action, which can lead to improved patient outcomes and reduced side effects compared to traditional treatments. Additionally, advancements in biotechnology and genomics are facilitating the development of novel protein therapeutics, further accelerating market growth and attracting significant investment from both pharmaceutical companies and research institutions.

Restraints in the Protein Therapeutics Market

One significant market restraint for the global protein therapeutics market is the high cost of development and manufacturing processes associated with protein-based drugs. The complexity of protein engineering, coupled with stringent regulatory requirements for approval, can lead to lengthy and expensive research phases. Additionally, the production of biologics often requires specialized facilities and equipment, further inflating costs. These financial barriers can limit the participation of smaller biotech companies and hinder innovations, ultimately affecting market availability and access to new therapeutic options for patients. As a result, high costs can impede overall market growth and adoption of protein therapeutics.

Market Trends of the Protein Therapeutics Market

The protein therapeutics market is experiencing a significant trend towards personalization, fueled by the increasing demand for tailored treatment solutions that align with individual genetic and molecular profiles. This shift not only enhances therapeutic efficacy but also minimizes adverse effects, making treatments more appealing to both healthcare providers and patients. As conditions like cancer and autoimmune diseases become more prevalent, the adoption of targeted biologics and advanced protein therapies is accelerating. This evolution reflects a broader move in healthcare towards precision medicine, driving innovation and investment in the development of sophisticated therapies that promise improved patient outcomes and a more effective healthcare system overall.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies
Insulin
Fusion Protein
Human Growth Hormone
Erythropoietin
Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2026-2033)

Market Overview
Cancer
Metabolic Disorders
Immunologic Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

Global Protein Therapeutics Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical companies
Healthcare Service Providers
Research Organizations
Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2026-2033)

Market Overview
Vaccines
Enzymatic and Regulatory
Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2026-2033)

North America (Type, Application, End User, Function)
- US
- Canada
Europe (Type, Application, End User, Function)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, End User, Function)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, End User, Function)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, End User, Function)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments